After spending nearly a decade in market access, my passion and expertise for understanding complex payer and channel dynamics allows me to rapidly assess the business implications on the biopharmaceutical industry.At Organon, we know the gap between biosimilar promise and adoption contributes to an overburdened US healthcare system, and making biosimilars sustainable is not only a socially responsible undertaking to pursue, but is fundamental to ensuring they have a commercially viable future.As a US Commercial Leader at Organon, I lead the commercial team in developing brand strategies for our robust and growing biosimilars portfolio.I also serve as a board member of the Biosimilars Forum where I act as a liaison to the biosimilar industry on policy matters that may facilitate cost savings to the healthcare system.The decade of biosimilars is upon us – are you ready?